WS #17005
Moderna delivered a massive earnings beat, with Q3 revenue of $1.3 billion significantly exceeding estimates and a sharp improvement in EPS. The company raised its full-year 2026 outlook, citing growing traction for newer vaccines. This performance stands in stark contrast to the broader tech and biotech selloff, highlighting that strong fundamentals and earnings growth can still command premium valuations even in a risk-off environment. Airbnb shares rose as the company reported better-than-expected Q3 results and announced a massive $12 billion share buyback program. This move signals management's confidence in the company's cash flow generation and commitment to returning capital to shareholders. Airbnb's performance bucked the broader travel and consumer discretionary weakness, highlighting the resilience of its brand and pricing power in the current economic climate.
Moderna Earnings Beat
Moderna delivered a massive earnings beat, with Q3 revenue of $1.3 billion significantly exceeding estimates and a sharp improvement in EPS. The company raised its full-year 2026 outlook, citing growing traction for newer vaccines. This performance stands in stark contrast to the broader tech and biotech selloff, highlighting that strong fundamentals and earnings growth can still command premium valuations even in a risk-off environment.
Airbnb shares rose as the company reported better-than-expected Q3 results and announced a massive $12 billion share buyback program. This move signals management's confidence in the company's cash flow generation and commitment to returning capital to shareholders. Airbnb's performance bucked the broader travel and consumer discretionary weakness, highlighting the resilience of its brand and pricing power in the current economic climate.